The incidence of ventilator-associated pneumonia using the PneuX System with or without elective endotracheal tube exchange: A pilot study by Doyle, Alex et al.
SHORT REPORT Open Access
The incidence of ventilator-associated pneumonia
using the PneuX System with or without elective
endotracheal tube exchange: A pilot study
Alex Doyle
*, Andrew Fletcher, Joseph Carter, Mark Blunt and Peter Young
Abstract
Background: The PneuX System is a novel endotracheal tube and tracheal seal monitor, which has been designed
to minimise the aspiration of oropharyngeal secretions. We aimed to determine the incidence of ventilator-
associated pneumonia (VAP) in patients who were intubated with the PneuX System and to establish whether
intermittent subglottic secretion drainage could be performed reliably and safely using the PneuX System.
Findings: In this retrospective observational study, data was collected from 53 sequential patients. Nine (17%)
patients were initially intubated with the PneuX System and 44 (83%) patients underwent elective exchange to the
PneuX System. There were no episodes of VAP while the PneuX System was in situ. On an intention to treat basis,
the incidence VAP was 1.8%. There were no complications from, or failure of, subglottic secretion drainage during
the study.
Conclusions: Our study demonstrates that a low incidence of VAP is possible using the PneuX System. Our study
also demonstrates that elective exchange and intermittent subglottic secretion drainage can be performed reliably
and safely using the PneuX System.
Introduction
Ventilator-associated pneumonia (VAP) can be defined
as a pneumonia that occurs after more than 48 hours of
intubation and mechanical ventilation [1]. The incidence
and mortality of VAP has been estimated to lie between
10-20% and 15-50% respectively, and it has been shown
to extend the length of stay in the intensive care unit
(ICU) and costs by at least 6 days and $10019 per epi-
sode [2]. With these figures in mind, the prevention of
VAP is of paramount importance. The aspiration of
contaminated secretions from the oropharyngeal space
is by far the most common cause of VAP [3]. Risk fac-
tors for the aspiration of oropharyngeal secretions in the
critically ill include [4]:
￿ Reintubation
￿ Accumulation of secretions above the endotracheal
tube cuff
￿ Colonisation of the upper airway with nosocomial
pathogens
￿ Inappropriate endotracheal tube cuff pressure
￿ Bacterial colonisation and biofilm formation inside
the endotracheal tube lumen
Subglottic secretion drainage (SSD) has been recom-
mended to minimise the accumulation of secretions
above the endotracheal tube (ETT) cuff [4-6]. This has
been shown to reduce the incidence of VAP by approxi-
mately 50%, but requires the use of a compatible device
such as the Hi-Lo Evac, SealGuard Evac, TaperGuard
(Covidien, Massachusetts, USA), Portex SACETT (Por-
tex, Hythe, UK) and the Teleflex ISIS HVT (Teleflex,
Wisconsin, USA) [4,7,8]. Frequently, patients are intu-
bated with a conventional ETT in the first instance. It
should be noted that there is no evidence to suggest
that electively reintubating a patient to exchange a con-
ventional ETT to a SSD compatible device is associated
with VAP [9].
The PneuX System (Venner Medical, Singapore)
comprises of a novel ETT and tracheal seal monitor
* Correspondence: ajdoyle@gmail.com
Department of Anaesthesia and Critical Care, Queen Elizabeth Hospital, Kings
Lynn, Norfolk, PE30 4ET, UK
Doyle et al. BMC Research Notes 2011, 4:92
http://www.biomedcentral.com/1756-0500/4/92
© 2011 Doyle et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.(figure 1 and 2). Unlike the other SSD compatible
devices, the PneuX System incorporates several strate-
gies to minimise the aspiration of oropharyngeal secre-
tions [10]. These include a securing flange, a unique
low-volume low-pressure (LVLP) cuff, multiple SSD
ports, a tracheal seal monitor and a coated tube lumen.
We aimed to determine the incidence of VAP in
patients who were initially intubated with the PneuX
System (primary intubation) or those who underwent
elective exchange to the PneuX System in our ICU. We
also aimed to establish whether intermittent subglottic
secretion drainage could be performed reliably and
safely using the PneuX System.
Methods
This retrospective observational study was conducted at
the Queen Elizabeth Hospital, Norfolk, UK with
approval from the Local Research and Ethics Commit-
tee. Prospective approval was obtained to report data
from our routine practice and for publication of
anonymised data. Written informed consent was
received for publication of the figures. All equipment
was used according to the manufacturers’ instructions.
Each patient was more than 18 years of age and
required intubation as part of his or her routine respira-
tory care. The use of the PneuX System was restricted
to those patients who were anticipated to require more
than 24 hours of intubation. All patients included in the
study were intubated with the PneuX System and
received mechanical ventilation for more than 48 hours.
No patients intubated with the PneuX System were
excluded from our analysis.
For the purpose of this study, VAP was defined as any
pneumonia that occurred after more than 48 hours of
intubation and mechanical ventilation with the PneuX
System. Ventilator-associated pneumonia was diagnosed
by (i) clinical suspicion (including the use of any anti-
biotics for the treatment of colonisation or infection
within the tracheobronchial tree or lungs); and/or
(ii) international consensus criteria: the presence of new,
persistent pulmonary infiltrates not otherwise explained,
appearing on chest radiographs and at least two of the
following criteria: temperature of > 38°C; leukocytosis >
10,000 cells/mm
3 and purulent respiratory secretions
[11]; and/or (iii) clinical pulmonary infection score (a
fall in the PaO2/FiO2 ratio >25% and a clinical pulmon-
ary infection score of >5 in the presence of bacteria in a
qualitative endotracheal aspirate).
Elective exchange was defined as elective reintubation
to change a conventional ETT to the PneuX System. If
a patient had previously been intubated with a conven-
tional ETT, elective exchange was performed once the
attending clinician predicted that at least a further 24
hours of ventilation was required. The procedure
involved using gastric tube aspiration, pre-procedural
pre-oxygenation, muscle relaxation and sedation, direct
laryngoscopy to clear upper airway secretions and a
bougie (appendix 1).
A standard protocol for the prevention of VAP was used
during the study period. This required patients to be
nursed in the head up position (between 30-45 degrees)
and intermittent SSD to be performed at 4 hourly inter-
vals. Decontamination of the subglottic space, larynx,
pharyngeal space and oral cavity was performed using
supracuff irrigation with a large volume of normal saline
(appendix 2). The cuff pressure was maintained for the
duration that the PneuX System was in situ by the tracheal
seal monitor alone. Airway humidification was provided
using a RT dual heated wire circuit, with MR290 Autofeed
Humidification Chamber (Fisher and Paykel, Auckland,
New Zealand). No new interventions for the prevention of
VAP were initiated during the study period other than the
use of the PneuX System. Neither oral chlorhexidine nor
oral antibiotic pastes were administered.
Figure 1 The PneuX System endotracheal tube.C u f fi ss h o w n
deflated. The subglottic drainage ports lie immediately superior to
the cuff.
Figure 2 The PneuX System tracheal seal monitor.
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physiology and chronic health evaluation II score, reason
for ICU admission, whether the patient was intubated
prior to ICU admission, whether a primary intubation
or elective exchange was performed, whether there was
any complication associated with elective exchange,
duration of intubation, the incidence of VAP, all micro-
biological data in addition to surveillance qualitative
endotracheal aspirates, which were performed 2-3 times
per week, and the mortality rate. The prescription of
antibiotics and reason for treatment was also recorded.
The number of SSD interventions and failure of SSD
due to blockage of the subglottic ports were recorded.
Failure of SSD was defined as an inability to perform
SSD because of subglottic drainage port blockage. Data
were entered into a spreadsheet and analysed using
Excel (Microsoft, California, USA).
Results
Data was collected from 53 sequential patients. The
demographic details are shown in Table 1.
Nine (17%) patients were initially intubated with the
PneuX System and 44 (83%) patients underwent elective
exchange to the PneuX System. There were no compli-
cations associated with elective exchange. There were a
total of 306 days of intubation. The mean duration of
intubation was 5.3 days +/- 4.1 (median duration of
intubation was 5 days and the interquartile range was
2-7 days). There were no episodes of VAP while the
PneuX System was in situ. On an intention to treat
basis, the incidence of VAP was 1.8%: one patient, who
had initially been intubated using the PneuX System,
underwent planned extubation and required emergency
reintubation for respiratory failure. A conventional ETT
was used for reintubation and the patient subsequently
developed a VAP after 48 hours. Forty eight (91%)
patients were treated with antibiotics prior to intubation.
Eighteen patients had their antibiotic treatment changed
following intubation (14; treatment of the underlying
condition, 3; suspected catheter related bloodstream
infection and 1; pseudomembranous colitis). No antibio-
tics were used to treat colonisation or new infection
within the tracheobronchialt r e eo rl u n g si nap a t i e n t s
intubated with the PneuX System. During this time,
there were a total of 728 SSD interventions. There was
no failure of SSD in a patients intubated with the
PneuX System.
Discussion
Our study demonstrated that there was a low incidence
of VAP in patients intubated with the PneuX System,
there were no complications associated elective
exchange to the PneuX System and intermittent SSD
and decontamination of the subglottic space, the larynx,
the pharyngeal space and the oral cavity can be per-
formed reliably and safely using the PneuX System.
Previously, the incidence of VAP has been estimated
to be much higher in general intensive care patients [2].
The low incidence of VAP in this study may be
explained by the fact that the PneuX System minimises
ap a t i e n t ’se x p o s u r et om u l t i p l er i s kf a c t o r sf o rV A P
[10]. The relative contribution of each strategy has not
been quantified. Therefore, we do not attribute the low
incidence of VAP to one strategy in particular.
This is the first article to demonstrate that elective
reintubation can be performed safety in the critically ill.
However, it should be noted that reintubation per se has
not been shown to increase the incidence of VAP. The
link between reintubation and VAP has only been
demonstrated following premature extubation, which
may be an accidental extubation or an intentional
planned extubation with the subsequent failure of venti-
lation [9]. Premature extubation leaves the lungs unpro-
tected against pulmonary aspiration. In this setting,
premature extubation has been estimated to increase the
relative risk of VAP by 5.3 times [12]. Our results sug-
gest that it may be safe to electively exchange a conven-
tional ETT to the PneuX System. This may not be
applicable to all other devices. The PneuX System is a
flexible armoured tube and has an atraumatic boat-tip
[10]. These features have been shown to ease reintuba-
tion over an introducer and passage through the glottis
when compared to a conventional ETT, which is more
rigid and has a bevel tip [13].
Our study also demonstrated that intermittent SSD
can be performed reliably and safely using the PneuX
System. Other SSD compatible devices have a single
subglottic drainage port have been shown to fail on 48%
of occasions, most commonly because of blockage of
t h es u b g l o t t i cd r a i n a g ep o r tb ys u c t i o n e dt r a c h e a l
Table 1 The patient demographic data
Variable Value (SD)
Mean age (years) 67.8 (15)
Gender (female/male) 22/31
Mean APACHE II score 22.4 (8.4)
Intubated prior to admission 21
Reason for ICU admission:
Cardiovascular 5
Respiratory 24
Gastrointestinal 17
Hepatorenal 2
Metabolic 2
Other 3
Mortality rate in ICU 19
APACHE II score; Acute Physiology and Chronic Health Evaluation II score. ICU;
Intensive care unit.
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tial subglottic drainage ports, which allow drainage to
proceed through the two unoccluded ports should one
of them become obstructed by suctioned tracheal
mucosa [10].
Other SSD compatible devices also have conventional
high volume low pressure cuffs, which have been shown
to allow subglottic secretions to leak around the cuff
[15]. Consequently, continuous aspiration has been used
to prevent the accumulation of secretions above the cuff.
However, this may produce ischaemic injury to suctioned
tracheal mucosa and therefore intermittent drainage is
commonly used [16,17]. In contrast, the PneuX System
has a unique LVLP cuff, which has been shown to com-
pletely prevent pulmonary aspiration [10,15]. Conse-
quently, it is safe to allow subglottic secretions to build
up above the cuff and perform intermittent SSD.
The superior performance of the LVLP cuff also
enables decontamination of the subglottic space, the lar-
ynx, the pharyngeal space and the oral cavity to be per-
formed using supracuff irrigation with a large volume of
normal saline. It was notable that once subglottic drai-
nage had been performed to dryness, a residual offensive
collection of upper airway fluid (estimated at 10-30 mL)
remained in the laryngopharynx. This residual material
was only cleared by irrigation with large volumes of nor-
mal saline (up to 300 mL).
An important limitation of this study was that the
incidence of VAP before introducing the PneuX System
was unknown. Therefore, the impact of introducing the
PneuX System could not be quantified. The retrospec-
tive nature of our study and the small number of
patients included in our analysis from a single institu-
tion also represent weaknesses of our study. However,
these represented all of the available patients at the
time. In light of this exciting pilot data, we now hope to
confirm our findings in prospective, multicentre studies
with larger patient groups and in independent centres.
In conclusion, our study demonstrates that a low inci-
dence of VAP is possible using the PneuX System. Our
study also demonstrates that elective exchange and
intermittent subglottic secretion drainage can be per-
formed reliably and safely using the PneuX System.
Appendix 1. Technique for elective endotracheal
tube exchange
1. Empty the stomach using a nasogastric or orogas-
tric tube
2. Apply 100% oxygen for 5 minutes
3. Provide neuromuscular blockade and sedation (as
per clinician’s judgment)
4. Perform direct laryngoscopy to clear upper airway
secretions
5. Use bougie (or other airway devices will be
allowed as per clinician’s discretion)
6. Once the endotracheal tube is inserted, the cuff
will be inflated in all groups with a syringe to an
end point of auditory air-seal
7. The endotracheal tube will then be attached to
the tracheal seal monitor to achieve air-seal (nor-
mally set at 20 mmHg or increased to 30 mmHg to
achieve air-seal)
Appendix 2. The procedure for supracuff
irrigation and decontamination of the subglottic
space, the larynx, the pharyngeal space and the
oral cavity
Aim:
￿ To irrigate the subglottic space, the larynx, the
pharyngeal space and the oral cavity using with 0.9%
sodium chloride until visually clean
Frequency:
￿ Perform once daily or more frequently if either the
subglottic aspirates or the oral cavity are offensive
Equipment:
￿ 50 mL 0.9% sodium chloride at room temperature
￿ 50 mL Luer syringe
￿ 10 mL Luer syringe
￿ Suction unit with Yankeur suction attachment
￿ Towel to protect the patients neck/chest/bed linen
from spillage
￿ Consider 5 mL 1-2% lignocaine if patient awake or
airway irritable
Procedure:
￿ Use clean technique
￿ Explain the procedure to the patient if awake
￿ Tracheal seal monitor set to at least 20 mmHg
￿ Flush the subglottic port with 5 mL of air to
ensure patency
￿ If patient awake consider pre-instillation of 5 mL
lignocaine through port and into subglottic space
￿ Fill the 50 mL Luer syringe with 50 mL 0.9%
sodium chloride
￿ Attach the syringe to the subglottic port on the
Lotrach
￿ Slowly instill the 50 mL 0.9% sodium chloride over
3-5 minutes whilst the other staff member uses the
Yankeur to remove the accumulating fluid from the
oral cavity
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Page 4 of 5￿ If the injection pressure is judged to be high then
the tracheal seal monitor will be increased to
50 mmHg for the duration of the irrigation
￿ 100-300 mL saline is used at the nurse’s discretion.
The volume used will be determined by the disconti-
nuation of irrigation once the secretions from the
mouth become visually non-offensive and predomi-
nantly saline
￿ Once all the saline has been infused, remove any
remaining fluid from the subglottic space by attach-
ing the 10 mL Luer syringe to the subglottic port
and apply suction over a 10-20 second period or
until the flow of fluid ceases
￿ Finally, remove the giving set from the subglottic
port
￿ During this procedure note any coughing, change
in cardiac rhythm and oxygen saturation, and reas-
sure the patient throughout.
￿ Discontinue if coughing or vagal bradycardia
occurs and consider warmer fluid and/or lignocaine
List of abbreviations
(VAP): Ventilator-associated pneumonia; (ICU): Intensive care unit. (SSD):
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